147 related articles for article (PubMed ID: 17953528)
1. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation.
Kakoulidou M; Giscombe R; Zhao X; Lefvert AK; Wang X
Scand J Immunol; 2007 Nov; 66(5):529-37. PubMed ID: 17953528
[TBL] [Abstract][Full Text] [Related]
2. The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation.
Inobe M; Aoki N; Linsley PS; Ledbetter JA; Abe R; Murakami M; Uede T
J Immunol; 1996 Jul; 157(2):582-8. PubMed ID: 8752905
[TBL] [Abstract][Full Text] [Related]
3. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.
Wong CK; Lit LC; Tam LS; Li EK; Lam CW
Rheumatology (Oxford); 2005 Aug; 44(8):989-94. PubMed ID: 15870153
[TBL] [Abstract][Full Text] [Related]
4. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
[TBL] [Abstract][Full Text] [Related]
5. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma.
Ip WK; Wong CK; Leung TF; Lam CW
Int Arch Allergy Immunol; 2005 May; 137(1):45-52. PubMed ID: 15785081
[TBL] [Abstract][Full Text] [Related]
6. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
[TBL] [Abstract][Full Text] [Related]
7. Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation.
Doty RT; Clark EA
J Immunol; 1996 Oct; 157(8):3270-9. PubMed ID: 8871621
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of the costimulatory molecules CD80, CD86, CD152, PD-1 and ICOS on T-cells from paracoccidioidomycosis patients: lack of correlation with T-cell hyporesponsiveness.
Cacere CR; Mendes-Giannini MJ; Fontes CJ; Kono A; Duarte AJ; Benard G
Clin Immunol; 2008 Nov; 129(2):341-9. PubMed ID: 18757242
[TBL] [Abstract][Full Text] [Related]
9. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
10. Identification of three alternatively spliced variants of human CD28 mRNA.
Magistrelli G; Jeannin P; Elson G; Gauchat JF; Nguyen TN; Bonnefoy JY; Delneste Y
Biochem Biophys Res Commun; 1999 May; 259(1):34-7. PubMed ID: 10334911
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning and mRNA tissue-expression of two isoforms of the ovine costimulatory molecule CD80 (B7-1).
Terzo EA; Alzueta M; Amorena B; de Andrés DF; de la Lastra JM
Vet Immunol Immunopathol; 2005 Jan; 103(1-2):9-19. PubMed ID: 15626458
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
Wang P; Liu Z; Wu C; Zhu B; Wang Y; Xu H
Transplant Proc; 2008 Oct; 40(8):2729-33. PubMed ID: 18929847
[TBL] [Abstract][Full Text] [Related]
13. Cross-species costimulation: relative contributions of CD80, CD86, and CD40.
Rogers NJ; Jackson IM; Jordan WJ; Hawadle MA; Dorling A; Lechler RI
Transplantation; 2003 Jun; 75(12):2068-76. PubMed ID: 12829914
[TBL] [Abstract][Full Text] [Related]
14. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
15. Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis.
Kakoulidou M; Wang X; Zhao X; Pirskanen R; Lefvert AK
J Neuroimmunol; 2007 Apr; 185(1-2):150-61. PubMed ID: 17346804
[TBL] [Abstract][Full Text] [Related]
16. Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli.
Cox GN; Pratt D; Smith D; McDermott MJ; Vanderslice RW
Protein Expr Purif; 1999 Oct; 17(1):26-32. PubMed ID: 10497065
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of soluble CTLA-4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children.
Ip WK; Wong CK; Leung TF; Lam CW
Pediatr Pulmonol; 2006 Jul; 41(7):674-82. PubMed ID: 16703581
[TBL] [Abstract][Full Text] [Related]
18. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
Habib-Agahi M; Jaberipour M; Searle PF
Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
[TBL] [Abstract][Full Text] [Related]
19. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway.
Ou D; Wang X; Metzger DL; Ao Z; Pozzilli P; James RF; Chen L; Warnock GL
Cell Transplant; 2006; 15(5):399-410. PubMed ID: 16970282
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of T cell proliferation by cholera toxin involves the modulation of costimulatory molecules CTLA-4 and CD28.
Vendetti S; Riccomi A; Sacchi A; Sciaraffia E; Gatta L; Pioli C; De Magistris MT
Immunol Lett; 2008 Jan; 115(1):59-69. PubMed ID: 18031829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
